Should You Blame Biogen for Medicare Part B Premium Hikes?

·4-min read

If you're enrolled in Medicare Part B, your premiums will increase quite a bit next year. The Centers for Medicare and Medicaid Services (CMS) singled out one drug as a key reason behind the coming hike: Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm. In this Motley Fool Live video recorded on Nov. 16, Fool contributors Keith Speights and Brian Orelli discuss whether beneficiaries should really blame Biogen for their higher Medicare Part B premiums.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting